Tin tức y dược
Breaking news, cập nhật luật, thông báo FDA / EMA / WHO / Bộ Y tế các nước.
- FDA
Convenience Kit Recall: Medical Action Industries Removes Convenience Kits Containing Namic RA Syringes
The adaptor on Namic RA syringes may unwind during use. The resulting loose connection or disconnection may lead to infection, blood loss, or air embolism.
- FDA
Pacemaker Correction: Boston Scientific Issues Correction for ACCOLADE Pacemakers and CRT-Ps
Brady SMR6 is now available for ACCOLADE pacemakers and CRT-Ps; correction expanded to include CRT-P and DR-EL devices.
- FDA
Convenience Kit Recall: American Contract Systems Removes Convenience Kits Containing Namic RA Syringes
The adaptor on Namic RA syringes may unwind during use. The resulting loose connection or disconnection may lead to infection, blood loss, or air embolism.
- cdc
JCB Flavors, LLC Issues Voluntary Recall of Topical Seasonings Due to Potential Health Risk
JCB Flavors, LLC of Watertown, Wisconsin, is voluntarily recalling select topical seasoning products due to the potential presence of Salmonella, an organism that can cause serious and sometimes fatal infections in young children, elderly individuals, and those with weakened immune systems.
- FDA
FDA Expands AI Capabilities and Completes Data Platform Consolidation
FDA announced major steps in its bold initiative to modernize the agency. The agency launched Elsa 4.0, a significant upgrade to the agency’s internal AI tool available to all FDA staff, from scientific reviewers to investigators.
- FDA
FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
FDA announced that it is piloting one-day inspectional assessments, as part of a broader initiative to make its inspectional resources more targeted and efficient.
- FDA
Disruptions in Availability of Neurosurgical Patties, Sponges, and Strips - Letter to Health Care Providers
The FDA issued a LHCP to notify providers that Neurosurgical Patties, Sponges, and Strips (product code HBA) are experiencing a supply disruption.
- FDA
FDA Expands Market Access, Authorizes New ENDS Products
FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.
- MedlinePlus
Developmental Monitoring and Screening
Source: Centers for Disease Control and PreventionRelated MedlinePlus Pages: Child Development, Developmental Disabilities, Infant and Newborn Development, Toddler Development
- FDA
Sizing Catheter Recall: Cook Medical Removes Various Centimeter Sizing Catheters
When the sizing catheters are used during angiographic procedures the marker bands may be at an increased risk of cracking/breakage.
- FDA
Surgical Stapler Reload Recall: Intuitive Surgical Removes 8mm SureForm 30 Gray Reloads
Certain SureForm Surgical Stapler reloads may form incomplete staple lines, leading to severe bleeding or death.
- FDA
Trividia Health Correction for TRUE METRIX Blood Glucose Monitoring Systems
FT. LAUDERDALE, FL – May 1, 2026 – Trividia Health, Inc., a global leader in diabetes management, today provided an important update to the medical device labeling correction it announced on February 6, 2026, for all TRUE METRIX®, TRUE METRIX® AIR, TRUE METRIX® GO, and TRUE METRIX® PRO Blood Glucose
- cdc
FSIS Issues Public Health Alert for Ravioli Pasta With Beef Sauce Due to Misbranding and Undeclared Allergenspha
WASHINGTON, May 4, 2026 - The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) is issuing a public health alert for ravioli pasta products due to misbranding and...
- WHO
Joint call by the President of the ICRC, the Director-General of WHO and the International President of MSF
Ten years ago, the UN Security Council unanimously adopted Resolution 2286 on health care in armed conflicts. The situation is even worse compared to 10 years ago. Today, we mark not an achievement – we mark a failure. As violence affecting medical facilities, transport and personnel continues unabated, the harm this resolution sought to prevent has not diminished. It has continued and, in many contexts, intensified. As the heads of the International Committee of the Red Cross (ICRC), the World Health Organization (WHO), and Médecins Sans Frontières (MSF), we join others in the international community in issuing an urgent call for action.
- WHO
WHO Member States agree to extend negotiations on Pathogen Access and Benefit Sharing annex
Member States of the World Health Organization (WHO) have progressed work on the Pathogen Access and Benefit Sharing (PABS) annex, a key part of the WHO Pandemic Agreement, and today agreed additional time was needed to finalize the framework for ensuring a better, more equitable, response to future pandemics.Countries today ended the resumed session of the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement in Geneva, focused on the PABS system. The outcome of this work will be presented to the Seventy-ninth World Health Assembly (WHA) later this month. Given the need for further negotiations, the Assembly will be asked to consider continuing IGWG s work as mandated in Resolution WHA78.1 and submit the outcome to the next Assembly in May 2027, or earlier by a special session of WHA in 2026. Real progress was made on the PABS annex and I am confident through continued negotiations differences will be overcome, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. Member States should continue approaching the outstanding issues with a sense of urgency because the next pandemic is a matter of when, not if. The PABS annex is the last piece of the puzzle not only for the Pandemic Agreement but all initiatives that WHO and Member States have implemented as a result of lessons learned from the COVID-19 pandemic. The PABS system is intended to ensure, on equal footing, the rapid sharing of pathogens with pandemic potential and the fair and equitable sharing of benefits arising from their use, such as vaccines, diagnostics and therapeutics. Finalizing the PABS Annex is necessary so countries can proceed with signature and ratification of the Pandemic Agreement. Finalizing a document of such technical and legal complexity requires precision and dedication, both of which the Member States have demonstrated in full, said IGWG Bureau Co-Chair Ambassador Tovar da Silva Nunes of Brazil. We are not there yet, but with an extension of our negotiations, we will get there. IGWG Co-Chair Mr Matthew Harpur said: WHO Member States have demonstrated strong and continuing commitment to negotiations on a Pathogen Access and Benefit Sharing system annex. The IGWG Bureau is confident we are moving in the right direction to finalize the PABS annex, and in doing so provide the WHO Pandemic Agreement with the framework needed to ensure countries are better, and more equitably, prepared and protected for the next pandemic. The IGWG will hold its seventh meeting from 6 to 17 July 2026.In May 2025, the World Health Assembly adopted the WHO Pandemic Agreement to strengthen how countries prevent, prepare for, and respond to pandemics. It also established an open-ended Intergovernmental Working Group (IGWG) to carry out key tasks, including drafting and negotiating the PABS system.
- FDA
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
- FDA
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.
- cdc
FSIS Issues Public Health Alert for Various Meat and Poultry Products Containing FDA-Regulated Dairy Products That Have Been Recalled Due to Possible Salmonella Contaminationpha
Last Updated: This release was last updated on May 15, 2026, to reflect additional affected products and their corresponding labels. WASHINGTON, APRIL 30, 2026 - The U.S. Department of Agriculture's...
- FDA
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
- FDA
Insulin Pump Recall: Insulet Removes Certain Omnipod 5 Pods
Omnipod Pods may not deliver insulin as intended due to a tear in the internal tubing.
- FDA
FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.
FDA announces results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market.
- EMA
EMA launches new advisory group on vaccine confidence
EMA has set up a new advisory group on vaccine confidence, which will advise the Agency on issues related to vaccine hesitancy and help guide its actions to increase science…, "Vaccine hesitancy is a growing global threat to public health. When public trust declines, infectious diseases can reemerge, putting lives at risk. EMA has a vital…, The advisory group on vaccine confidence will meet quarterly. It includes academics, representatives of healthcare professionals, medical societies and patient organisations, as…
- WHO
Australia becomes the 30th country to eliminate trachoma as a public health problem
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.
- FDA
FDA Announces Major Steps to Implement Real-Time Clinical Trials
The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).
- MedlinePlus
What Is Anal Cancer?
Source: National Cancer Institute - Related MedlinePlus Pages: Anal Cancer